<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00284518</url>
  </required_header>
  <id_info>
    <org_study_id>191622-517</org_study_id>
    <nct_id>NCT00284518</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the safety and effectiveness of different doses of
      botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic
      hyperplasia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in International Prostate Symptom Score (IPSS) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The International Prostate Symptom Score is a disease-specific outcome measure based on the American Urological Association Symptom Index. The questionnaire consists of seven items. The patient evaluates their urinary symptoms (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, and nocturia) during the previous 4 weeks. The total symptom score can range from 0 (no symptoms) to 35 (most severe symptoms). A negative change from baseline indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in International Prostate Symptom Score (IPSS) at Week 72</measure>
    <time_frame>Baseline, Week 72</time_frame>
    <description>The International Prostate Symptom Score is a disease-specific outcome measure based on the American Urological Association Symptom Index. The questionnaire consists of seven items. The patient evaluates their urinary symptoms (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, and nocturia) during the previous 4 weeks. The total symptom score can range from 0 (no symptoms) to 35 (most severe symptoms). A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak Urine Flow Rate</measure>
    <time_frame>Baseline, Week 12, Week 72</time_frame>
    <description>Urinary flow was determined by uroflowmetry at baseline and various time-points during the study. An increase from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Prostate Volume</measure>
    <time_frame>Baseline, Week 12, Week 72</time_frame>
    <description>Measurement of the prostate volume was performed via transrectal ultrasound at baseline and various time-points during the study. The prostate gland was scanned and the volume was calculated using the formula: Volume (mL) = length × width × height × 0.523. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Transitional Zone Prostate Volume</measure>
    <time_frame>Baseline, Week 12, Week 72</time_frame>
    <description>Measurement of the transitional zone prostate volume was performed via transrectal ultrasound at baseline and various time-points during the study. The prostate gland was scanned and the volume was calculated using the formula: Volume (mL) = length × width × height × 0.523. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Post-Void Residual</measure>
    <time_frame>Baseline, Week 2, Week 12, Week 72</time_frame>
    <description>Post-void residual urine volume was assessed by bladder scan or ultrasound on all participants at baseline and various time-points during the study. After voiding, any residual urine volume in the bladder was measured. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in the International Index of Erectile Function (IIEF) Questionnaire Erectile Function Domain</measure>
    <time_frame>Baseline, Week 12, Week 72</time_frame>
    <description>The IIEF is a 15-item questionnaire filled out by the patient to assess erectile function over the past 4 weeks that contains five domains. The score for the erectile function domain is the sum of scores for Questions 1, 2, 3, 4, 5 and 15 for a total possible score of 1 to 30. A higher score indicates a better outcome. A positive change from baseline indicates improvement.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">380</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>botulinum toxin Type A 300 U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>botulinum toxin Type A 200 U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>botulinum toxin Type A 100 U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Normal Saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Normal Saline) transperineal or transrectal injection on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin Type A</intervention_name>
    <description>Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.</description>
    <arm_group_label>botulinum toxin Type A 300 U</arm_group_label>
    <arm_group_label>botulinum toxin Type A 200 U</arm_group_label>
    <arm_group_label>botulinum toxin Type A 100 U</arm_group_label>
    <other_name>BOTOX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Normal Saline (Placebo) transperineal or transrectal injection on Day 1.</description>
    <arm_group_label>Placebo (Normal Saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lower urinary tract symptoms due to benign prostatic hyperplasia

          -  Enlarged prostate volume by rectal ultrasound

        Exclusion Criteria:

          -  Previous prostate surgery

          -  Previous or current diagnosis of prostate cancer

          -  Use of other medications for the treatment of prostatic hyperplasia

          -  Urinary tract infection
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Murdoch</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 13</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Slovakia</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2006</study_first_submitted>
  <study_first_submitted_qc>January 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2006</study_first_posted>
  <results_first_submitted>November 16, 2012</results_first_submitted>
  <results_first_submitted_qc>November 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2012</results_first_posted>
  <disposition_first_submitted>February 3, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 3, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 8, 2010</disposition_first_posted>
  <last_update_submitted>November 16, 2012</last_update_submitted>
  <last_update_submitted_qc>November 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Botulinum Toxin Type A 300 U</title>
          <description>Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Botulinum Toxin Type A 200 U</title>
          <description>Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Botulinum Toxin Type A 100 U</title>
          <description>Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Placebo (Normal Saline)</title>
          <description>Placebo (Normal Saline) transperineal or transrectal injection on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="95"/>
                <participants group_id="P4" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Botulinum Toxin Type A 300 U</title>
          <description>Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Botulinum Toxin Type A 200 U</title>
          <description>Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Botulinum Toxin Type A 100 U</title>
          <description>Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Placebo (Normal Saline)</title>
          <description>Placebo (Normal Saline) transperineal or transrectal injection on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
            <count group_id="B2" value="94"/>
            <count group_id="B3" value="95"/>
            <count group_id="B4" value="94"/>
            <count group_id="B5" value="380"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>45 to 65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="94"/>
                    <measurement group_id="B5" value="380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in International Prostate Symptom Score (IPSS) at Week 12</title>
        <description>The International Prostate Symptom Score is a disease-specific outcome measure based on the American Urological Association Symptom Index. The questionnaire consists of seven items. The patient evaluates their urinary symptoms (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, and nocturia) during the previous 4 weeks. The total symptom score can range from 0 (no symptoms) to 35 (most severe symptoms). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Participants from the intent-to-treat population (includes all randomized participants) with data available for analyses at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 300 U</title>
            <description>Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 200 U</title>
            <description>Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Toxin Type A 100 U</title>
            <description>Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo (Normal Saline) transperineal or transrectal injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Prostate Symptom Score (IPSS) at Week 12</title>
          <description>The International Prostate Symptom Score is a disease-specific outcome measure based on the American Urological Association Symptom Index. The questionnaire consists of seven items. The patient evaluates their urinary symptoms (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, and nocturia) during the previous 4 weeks. The total symptom score can range from 0 (no symptoms) to 35 (most severe symptoms). A negative change from baseline indicates improvement.</description>
          <population>Participants from the intent-to-treat population (includes all randomized participants) with data available for analyses at the given time-point.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="6.03"/>
                    <measurement group_id="O2" value="20.2" spread="5.80"/>
                    <measurement group_id="O3" value="21.5" spread="5.42"/>
                    <measurement group_id="O4" value="20.7" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12 (N=86,89,93,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="7.73"/>
                    <measurement group_id="O2" value="-6.3" spread="7.13"/>
                    <measurement group_id="O3" value="-6.6" spread="6.87"/>
                    <measurement group_id="O4" value="-5.5" spread="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in International Prostate Symptom Score (IPSS) at Week 72</title>
        <description>The International Prostate Symptom Score is a disease-specific outcome measure based on the American Urological Association Symptom Index. The questionnaire consists of seven items. The patient evaluates their urinary symptoms (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, and nocturia) during the previous 4 weeks. The total symptom score can range from 0 (no symptoms) to 35 (most severe symptoms). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 72</time_frame>
        <population>Participants from the intent-to-treat population (includes all randomized participants) with data available for analyses at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 300 U</title>
            <description>Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 200 U</title>
            <description>Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Toxin Type A 100 U</title>
            <description>Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo (Normal Saline) transperineal or transrectal injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Prostate Symptom Score (IPSS) at Week 72</title>
          <description>The International Prostate Symptom Score is a disease-specific outcome measure based on the American Urological Association Symptom Index. The questionnaire consists of seven items. The patient evaluates their urinary symptoms (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, and nocturia) during the previous 4 weeks. The total symptom score can range from 0 (no symptoms) to 35 (most severe symptoms). A negative change from baseline indicates improvement.</description>
          <population>Participants from the intent-to-treat population (includes all randomized participants) with data available for analyses at the given time-point.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="6.03"/>
                    <measurement group_id="O2" value="20.2" spread="5.80"/>
                    <measurement group_id="O3" value="21.5" spread="5.42"/>
                    <measurement group_id="O4" value="20.7" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 72 (N=64,61,66,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="6.50"/>
                    <measurement group_id="O2" value="-4.1" spread="6.40"/>
                    <measurement group_id="O3" value="-4.7" spread="7.15"/>
                    <measurement group_id="O4" value="-4.3" spread="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak Urine Flow Rate</title>
        <description>Urinary flow was determined by uroflowmetry at baseline and various time-points during the study. An increase from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 12, Week 72</time_frame>
        <population>Participants from the intent-to-treat population (includes all randomized participants) with data available for analyses at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 300 U</title>
            <description>Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 200 U</title>
            <description>Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Toxin Type A 100 U</title>
            <description>Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo (Normal Saline) transperineal or transrectal injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak Urine Flow Rate</title>
          <description>Urinary flow was determined by uroflowmetry at baseline and various time-points during the study. An increase from baseline indicates improvement.</description>
          <population>Participants from the intent-to-treat population (includes all randomized participants) with data available for analyses at the given time-point.</population>
          <units>milliliters (mL)/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="2.70"/>
                    <measurement group_id="O2" value="10.6" spread="2.83"/>
                    <measurement group_id="O3" value="9.6" spread="2.57"/>
                    <measurement group_id="O4" value="10.1" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 12 (N=81,80,86,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="4.65"/>
                    <measurement group_id="O2" value="2.0" spread="4.98"/>
                    <measurement group_id="O3" value="2.7" spread="5.21"/>
                    <measurement group_id="O4" value="2.8" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 72 (N=59,56,64,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="4.67"/>
                    <measurement group_id="O2" value="2.4" spread="5.18"/>
                    <measurement group_id="O3" value="2.0" spread="4.07"/>
                    <measurement group_id="O4" value="2.3" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Prostate Volume</title>
        <description>Measurement of the prostate volume was performed via transrectal ultrasound at baseline and various time-points during the study. The prostate gland was scanned and the volume was calculated using the formula: Volume (mL) = length × width × height × 0.523. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 12, Week 72</time_frame>
        <population>Participants from the intent-to-treat population (includes all randomized participants) with data available for analyses at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 300 U</title>
            <description>Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 200 U</title>
            <description>Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Toxin Type A 100 U</title>
            <description>Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo (Normal Saline) transperineal or transrectal injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Prostate Volume</title>
          <description>Measurement of the prostate volume was performed via transrectal ultrasound at baseline and various time-points during the study. The prostate gland was scanned and the volume was calculated using the formula: Volume (mL) = length × width × height × 0.523. A negative change from baseline indicates improvement.</description>
          <population>Participants from the intent-to-treat population (includes all randomized participants) with data available for analyses at the given time-point.</population>
          <units>milliliter (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.78" spread="16.800"/>
                    <measurement group_id="O2" value="48.40" spread="16.325"/>
                    <measurement group_id="O3" value="47.54" spread="16.917"/>
                    <measurement group_id="O4" value="47.23" spread="14.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12 (N=86,84,88,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.40" spread="10.046"/>
                    <measurement group_id="O2" value="-3.65" spread="9.255"/>
                    <measurement group_id="O3" value="-3.54" spread="9.823"/>
                    <measurement group_id="O4" value="-4.59" spread="8.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 72 (N=65,60,67,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.58" spread="9.773"/>
                    <measurement group_id="O2" value="-2.82" spread="11.194"/>
                    <measurement group_id="O3" value="-1.77" spread="10.714"/>
                    <measurement group_id="O4" value="-2.69" spread="10.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Transitional Zone Prostate Volume</title>
        <description>Measurement of the transitional zone prostate volume was performed via transrectal ultrasound at baseline and various time-points during the study. The prostate gland was scanned and the volume was calculated using the formula: Volume (mL) = length × width × height × 0.523. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 12, Week 72</time_frame>
        <population>Participants from the intent-to-treat population (includes all randomized participants) with data available for analyses at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 300 U</title>
            <description>Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 200 U</title>
            <description>Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Toxin Type A 100 U</title>
            <description>Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo (Normal Saline) transperineal or transrectal injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Transitional Zone Prostate Volume</title>
          <description>Measurement of the transitional zone prostate volume was performed via transrectal ultrasound at baseline and various time-points during the study. The prostate gland was scanned and the volume was calculated using the formula: Volume (mL) = length × width × height × 0.523. A negative change from baseline indicates improvement.</description>
          <population>Participants from the intent-to-treat population (includes all randomized participants) with data available for analyses at the given time-point.</population>
          <units>milliliters (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.78" spread="14.657"/>
                    <measurement group_id="O2" value="21.75" spread="12.931"/>
                    <measurement group_id="O3" value="21.00" spread="14.188"/>
                    <measurement group_id="O4" value="20.73" spread="13.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12 (N=83,82,86,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="6.516"/>
                    <measurement group_id="O2" value="-0.76" spread="8.085"/>
                    <measurement group_id="O3" value="-0.02" spread="8.445"/>
                    <measurement group_id="O4" value="-0.27" spread="6.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 72 (N=64,59,65,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="7.655"/>
                    <measurement group_id="O2" value="-0.94" spread="8.119"/>
                    <measurement group_id="O3" value="-0.35" spread="8.808"/>
                    <measurement group_id="O4" value="-1.35" spread="6.801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Post-Void Residual</title>
        <description>Post-void residual urine volume was assessed by bladder scan or ultrasound on all participants at baseline and various time-points during the study. After voiding, any residual urine volume in the bladder was measured. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 2, Week 12, Week 72</time_frame>
        <population>Participants from the safety population (includes all randomized and treated participants) with data available for analyses at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 300 U</title>
            <description>Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 200 U</title>
            <description>Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Toxin Type A 100 U</title>
            <description>Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo (Normal Saline) transperineal or transrectal injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post-Void Residual</title>
          <description>Post-void residual urine volume was assessed by bladder scan or ultrasound on all participants at baseline and various time-points during the study. After voiding, any residual urine volume in the bladder was measured. A negative change from baseline indicates improvement.</description>
          <population>Participants from the safety population (includes all randomized and treated participants) with data available for analyses at the given time-point.</population>
          <units>milliliters (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="57.07"/>
                    <measurement group_id="O2" value="69.7" spread="54.93"/>
                    <measurement group_id="O3" value="66.1" spread="55.59"/>
                    <measurement group_id="O4" value="64.3" spread="51.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 2 (N=76,82,80,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="64.06"/>
                    <measurement group_id="O2" value="10.9" spread="88.62"/>
                    <measurement group_id="O3" value="-1.4" spread="65.01"/>
                    <measurement group_id="O4" value="1.6" spread="61.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12 (N=88,84,89,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="78.18"/>
                    <measurement group_id="O2" value="9.0" spread="81.23"/>
                    <measurement group_id="O3" value="-1.4" spread="62.82"/>
                    <measurement group_id="O4" value="3.2" spread="57.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 72 (N=66,60,65,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="73.27"/>
                    <measurement group_id="O2" value="-12.4" spread="54.31"/>
                    <measurement group_id="O3" value="14.0" spread="75.97"/>
                    <measurement group_id="O4" value="6.0" spread="69.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in the International Index of Erectile Function (IIEF) Questionnaire Erectile Function Domain</title>
        <description>The IIEF is a 15-item questionnaire filled out by the patient to assess erectile function over the past 4 weeks that contains five domains. The score for the erectile function domain is the sum of scores for Questions 1, 2, 3, 4, 5 and 15 for a total possible score of 1 to 30. A higher score indicates a better outcome. A positive change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 12, Week 72</time_frame>
        <population>Participants from the intent-to-treat population (includes all randomized participants) with data available for analyses at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 300 U</title>
            <description>Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 200 U</title>
            <description>Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Toxin Type A 100 U</title>
            <description>Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo (Normal Saline) transperineal or transrectal injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the International Index of Erectile Function (IIEF) Questionnaire Erectile Function Domain</title>
          <description>The IIEF is a 15-item questionnaire filled out by the patient to assess erectile function over the past 4 weeks that contains five domains. The score for the erectile function domain is the sum of scores for Questions 1, 2, 3, 4, 5 and 15 for a total possible score of 1 to 30. A higher score indicates a better outcome. A positive change from baseline indicates improvement.</description>
          <population>Participants from the intent-to-treat population (includes all randomized participants) with data available for analyses at the given time-point.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="10.20"/>
                    <measurement group_id="O2" value="14.6" spread="10.7"/>
                    <measurement group_id="O3" value="17.2" spread="10.19"/>
                    <measurement group_id="O4" value="16.7" spread="10.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12 (N=80,72,83,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="6.66"/>
                    <measurement group_id="O2" value="-0.2" spread="5.54"/>
                    <measurement group_id="O3" value="-0.9" spread="6.93"/>
                    <measurement group_id="O4" value="1.3" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 72 (N=61,54,61,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="7.17"/>
                    <measurement group_id="O2" value="0.5" spread="4.56"/>
                    <measurement group_id="O3" value="-1.5" spread="7.34"/>
                    <measurement group_id="O4" value="-0.9" spread="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline in IPSS at Week 12 in Patients Previously Treated With Alpha-blockers</title>
        <description>The International Prostate Symptom Score (IPSS) is a disease-specific outcome measure based on the American Urological Association Symptom Index. The questionnaire consists of seven items. The patient evaluates their urinary symptoms (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, and nocturia) during the previous 4 weeks. The total symptom score can range from 0 (no symptoms) to 35 (most severe symptoms). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Participants from the Intent-to-treat population previously treated with alpha-blockers with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A 300 U</title>
            <description>Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Botulinum Toxin Type A 200 U</title>
            <description>Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Botulinum Toxin Type A 100 U</title>
            <description>Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Normal Saline)</title>
            <description>Placebo (Normal Saline) transperineal or transrectal injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IPSS at Week 12 in Patients Previously Treated With Alpha-blockers</title>
          <description>The International Prostate Symptom Score (IPSS) is a disease-specific outcome measure based on the American Urological Association Symptom Index. The questionnaire consists of seven items. The patient evaluates their urinary symptoms (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, and nocturia) during the previous 4 weeks. The total symptom score can range from 0 (no symptoms) to 35 (most severe symptoms). A negative change from baseline indicates improvement.</description>
          <population>Participants from the Intent-to-treat population previously treated with alpha-blockers with data available for analyses.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="6.20"/>
                    <measurement group_id="O2" value="19.6" spread="6.15"/>
                    <measurement group_id="O3" value="21.9" spread="5.65"/>
                    <measurement group_id="O4" value="20.4" spread="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12 (N=44,35,52,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="7.76"/>
                    <measurement group_id="O2" value="-6.6" spread="5.91"/>
                    <measurement group_id="O3" value="-5.4" spread="5.17"/>
                    <measurement group_id="O4" value="-3.5" spread="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety population was used to calculate the number of participants at risk for Serious Adverse Events and Adverse Events and was defined as all randomized and treated participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Botulinum Toxin Type A 300 U</title>
          <description>Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Botulinum Toxin Type A 200 U</title>
          <description>Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Botulinum Toxin Type A 100 U</title>
          <description>Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Placebo (Normal Saline)</title>
          <description>Placebo (Normal Saline) transperineal or transrectal injection on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Retinal artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Corneal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Bacterial prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prostatic specific antigen increase</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Haematospermia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

